Physician profile
Sara Rummelhoff
NPI 1497277354
$2,143.00
in general payments reported to CMS, 2019-2025
20 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $900 · 2022: $226 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825 · Travel and Lodging: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.28 |
| Travel and Lodging | $191.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $243.41 | 2021 | |
| Edwards Lifesciences Corporation | $216.38 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $213.79 | 2022-2025 | Corevalve Evolut R |
| Abbott Laboratories | $195.00 | 2025 | Navitor |
| Heartflow, INC. | $191.83 | 2025 | |
| Glaxosmithkline, LLC. | $186.38 | 2021-2022 | |
| Biosense Webster, INC. | $146.86 | 2025 | Carto 3 |
| Ucb, INC. | $144.89 | 2021 | |
| Alexion Pharmaceuticals, INC. | $141.06 | 2021 | |
| Amgen INC. | $82.74 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.42 | 2021-2022 | |
| Lundbeck LLC | $65.76 | 2021-2022 | |
| Boston Scientific Corporation | $65.05 | 2025 | Watchman Flx |
| Daiichi Sankyo INC. | $35.19 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $28.09 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $25.33 | 2021 | |
| Janssen Biotech, INC. | $23.22 | 2021 | |
| Genentech USA, INC. | $22.82 | 2021 | |
| Horizon Therapeutics Plc | $19.48 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Rummelhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.